Key points are not available for this paper at this time.
Abstract Lipid-based colloidal carriers, particularly Solid Lipid Nanoparticles (SLNs), offer a versatile platform for formulating hydrophobic drugs, presenting significant pharmaceutical implications across diverse fields. This paper explores methodologies utilized in SLN production, ranging from high-pressure homogenization to microemulsion techniques, with each method influencing the characteristics and efficacy of the resultant nanoparticles. Various administration routes for SLNs exist, leveraging the lipid matrix's protective properties to shield encapsulated drugs, thus minimizing degradation and enhancing therapeutic efficacy. Furthermore, SLNs exhibit sustained release properties, facilitating prolonged drug delivery and reducing the need for frequent dosing. Their small size and high surface area contribute to improved drug dissolution, enhanced bioavailability, and extended retention within the body. The existence of multiple patents underscores the substantial research conducted in the domain of SLNs, with numerous commercial formulations available globally. In conclusion, this work highlights the intricate nature of SLNs and their pivotal role in advancing drug delivery techniques. Ongoing efforts are directed toward overcoming challenges and exploring novel therapeutic avenues, highlighting the dynamic and evolving landscape of SLN research and application.
Bukke et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: